147 related articles for article (PubMed ID: 17854311)
21. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
Hochster HS; Oken MM; Winter JN; Gordon LI; Raphael BG; Bennett JM; Cassileth PA
J Clin Oncol; 2000 Mar; 18(5):987-94. PubMed ID: 10694548
[TBL] [Abstract][Full Text] [Related]
23. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine in low-grade lymphoma.
Pigaditou A; Rohatiner AZ; Whelan JS; Johnson PW; Ganjoo RK; Rossi A; Norton AJ; Amess J; Lim J; Lister TA
Semin Oncol; 1993 Oct; 20(5 Suppl 7):24-7. PubMed ID: 8235692
[TBL] [Abstract][Full Text] [Related]
25. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
[TBL] [Abstract][Full Text] [Related]
26. Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Kohori M; Aoki S; Miura I; Hirano M
Hematol Oncol; 2006 Dec; 24(4):220-6. PubMed ID: 16958147
[TBL] [Abstract][Full Text] [Related]
27. [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
Gershanovich ML; Tikhonova VV
Vopr Onkol; 2004; 50(5):602-4. PubMed ID: 15715106
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
[TBL] [Abstract][Full Text] [Related]
30. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
[TBL] [Abstract][Full Text] [Related]
31. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M;
Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579
[TBL] [Abstract][Full Text] [Related]
32. Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
Palomera L; Azaceta G; Varo MJ; Soria J; Gutierrez M
Haematologica; 1998 Nov; 83(11):1045-6. PubMed ID: 9864929
[TBL] [Abstract][Full Text] [Related]
33. Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC).
Bocchia M; Gentili S; Forconi F; le Noci M; Tozzi M; Lauria F
Haematologica; 2003 Mar; 88(3):358-60. PubMed ID: 12651282
[No Abstract] [Full Text] [Related]
34. Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
Waselenko JK; Burrows A; Nelson DA; Lucas M; Ekstrand J; Edenfield WJ; Myhand RC
Ann Hematol; 2003 Sep; 82(9):552-7. PubMed ID: 12910372
[TBL] [Abstract][Full Text] [Related]
35. Low-dose epirubicin in combination with cyclophosphamide, vinblastine and prednisone (mini-CEOP) for the treatment of aggressive non-Hodgkin's lymphoma in elderly patients.
Veneri D; Zanetti F; Franchini M; Krampera M; Pizzolo G
Haematologica; 2002 Nov; 87(11):ELT43. PubMed ID: 12414364
[No Abstract] [Full Text] [Related]
36. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
37. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
Kasamon YL; Flinn IW; Grever MR; Diehl LF; Garrett-Mayer E; Goodman SN; Lucas MS; Byrd JC
Clin Cancer Res; 2005 Dec; 11(23):8413-7. PubMed ID: 16322303
[TBL] [Abstract][Full Text] [Related]
39. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
[TBL] [Abstract][Full Text] [Related]
40. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
